These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32092629)

  • 1. Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.
    Kaltashov IA; Bobst CE; Pawlowski J; Wang G
    J Pharm Biomed Anal; 2020 May; 184():113169. PubMed ID: 32092629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.
    Kaltashov IA; Bobst CE; Abzalimov RR; Berkowitz SA; Houde D
    J Am Soc Mass Spectrom; 2010 Mar; 21(3):323-37. PubMed ID: 19963397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
    Bobst CE; Kaltashov IA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1517-29. PubMed ID: 21542797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MS-based conformation analysis of recombinant proteins in design, optimization and development of biopharmaceuticals.
    Goswami D; Zhang J; Bondarenko PV; Zhang Z
    Methods; 2018 Jul; 144():134-151. PubMed ID: 29678586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.
    Kaltashov IA; Bobst CE; Abzalimov RR; Wang G; Baykal B; Wang S
    Biotechnol Adv; 2012; 30(1):210-22. PubMed ID: 21619926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.
    Huang RY; Chen G
    Anal Bioanal Chem; 2014 Oct; 406(26):6541-58. PubMed ID: 24948090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogen deuterium exchange mass spectrometry in biopharmaceutical discovery and development - A review.
    Deng B; Lento C; Wilson DJ
    Anal Chim Acta; 2016 Oct; 940():8-20. PubMed ID: 27662755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utilization of Hydrogen/Deuterium Exchange in Biopharmaceutical Industry].
    Coufalová D; Vojtěšek B; Hernychova L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):59-63. PubMed ID: 27846722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen/deuterium exchange-mass spectrometry analysis of high concentration biotherapeutics: application to phase-separated antibody formulations.
    Tian Y; Huang L; Ruotolo BT; Wang N
    MAbs; 2019; 11(4):779-788. PubMed ID: 30890021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Aggregation Propensity of a Human Fc-Fusion Protein Therapeutic by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Huang RY; Iacob RE; Krystek SR; Jin M; Wei H; Tao L; Das TK; Tymiak AA; Engen JR; Chen G
    J Am Soc Mass Spectrom; 2017 May; 28(5):795-802. PubMed ID: 27527097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution MS for structural characterization of protein therapeutics: advances and future directions.
    Wei H; Tymiak AA; Chen G
    Bioanalysis; 2013 May; 5(10):1299-313. PubMed ID: 23721450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational Assessment of Adnectin and Adnectin-Drug Conjugate by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Huang RY; O'Neil SR; Lipovšek D; Chen G
    J Am Soc Mass Spectrom; 2018 Jul; 29(7):1524-1531. PubMed ID: 29736601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in LC-MS based characterization of protein-based bio-therapeutics - mastering analytical challenges posed by the increasing format complexity.
    Graf T; Heinrich K; Grunert I; Wegele H; Haberger M; Bulau P; Leiss M
    J Pharm Biomed Anal; 2020 Jul; 186():113251. PubMed ID: 32251978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical characterization of biopharmaceuticals.
    Parr MK; Montacir O; Montacir H
    J Pharm Biomed Anal; 2016 Oct; 130():366-389. PubMed ID: 27324698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in native high-performance liquid chromatography and intact mass spectrometry for the characterization of biopharmaceutical products.
    Tassi M; De Vos J; Chatterjee S; Sobott F; Bones J; Eeltink S
    J Sep Sci; 2018 Jan; 41(1):125-144. PubMed ID: 28990739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring the hydrogen/deuterium exchange of proteins at high spatial resolution by mass spectrometry: overcoming gas-phase hydrogen/deuterium scrambling.
    Rand KD; Zehl M; Jørgensen TJ
    Acc Chem Res; 2014 Oct; 47(10):3018-27. PubMed ID: 25171396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mass spectrometry in biologics discovery: advances and future trends.
    Mo J; Tymiak AA; Chen G
    Drug Discov Today; 2012 Dec; 17(23-24):1323-30. PubMed ID: 22819924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.
    Houde D; Berkowitz SA; Engen JR
    J Pharm Sci; 2011 Jun; 100(6):2071-86. PubMed ID: 21491437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mass spectrometry in the characterization of biologic protein products.
    Rathore D; Faustino A; Schiel J; Pang E; Boyne M; Rogstad S
    Expert Rev Proteomics; 2018 May; 15(5):431-449. PubMed ID: 29694790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.